From bedside to bench to bedside to clinical practice: An odyssey with irinotecan

Clinical Cancer Research

Volumn 12, Issue 6, 2006, Pages 1658-1660

  Ratain, Mark J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CYCLOSPORIN A; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; PHENOBARBITAL;

CLINICAL PRACTICE; CLINICAL TRIAL; CRIGLER NAJJAR SYNDROME; DIARRHEA; DOSE RESPONSE; DRUG INHIBITION; DRUG METABOLISM; GASTROINTESTINAL TOXICITY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GILBERT DISEASE; GLUCURONIDATION; HUMAN; NEUTROPENIA; NONHUMAN; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; GLUCURONOSYLTRANSFERASE; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; TECHNOLOGY TRANSFER; TECHNOLOGY, PHARMACEUTICAL;

EID: 33645686466     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0159     Document Type: Review

References (23)

1. WordNet [database on the internet]. Princeton (NJ): Princeton University, Cognitive Science Laboratory [cited 2006 Jan 18]. Available from: http://wordnet. princeton.edu/perl/webwn.
2. Vokes EE, Janisch L, Spector B, et al. A phase I dose-intensification study of irinotecan (CPT-11) with maximized supportive care. Cancer Ther 1998;1:223-8.
3. Gupta E, Lestingi TM, Mick R, et al. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 1994;54:3723-5.
4. Gupta E, Mick R, Ramirez J, et al. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol 1997;15:1502-10.
5. Gupta E, Safa AR, Wang X, Ratain MJ. Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A. Cancer Res 1996;56:1309-14.
6. Innocenti F, Undevia SD, Ramirez J, et al. A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital. Clin Pharmacol Ther 2004;76:490-502.
7. Desai AA, Kindler HL, Taber D, et al. Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer. Cancer Chemother Pharmacol 2005;56:421-6.
8. Iyer L, King CD, Whitington PF, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998;101:847-54.
9. Bosma PJ, Chowdhury JR, Bakker C, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995;333:1171-5.
10. Monaghan G, Ryan M, Seddon R, Hume R, Burchell B. Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 1996;347:578-81.
11. Gong QH, Cho JW, Huang T, et al. Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics 2001;11:357-68.
12. Iyer L, Hall D, Das S, et al. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 1999;65:576-82.
13. Ratain MJ, Gupta E, inventors. Camptothecin drug combinations and methods with reduced side effects. United States patent US 5786344. 1998 Jul 28.
14. Iyer L, Das S, Janisch L, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002;2:43-7.
15. Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004;22:1382-8.
16. Taub S, Morin K, Spillman MA, Sade RM, Riddick FA. Managing familial risk in genetic testing. Genet Test 2004;8:356-9.
17. Huang YY, Huang CS, Yang SS, Lin MS, Huang MJ. Effects of variant UDP-glucuronosyltransferase 1A1 gene, glucose-6-phosphate dehydrogenase deficiency and thalassemia on cholelithiasis. World J Gastroenterol 2005;11:5710-3.
18. Duguay Y, McGrath M, Lepine J, et al. The functional UGT1A1 promoter polymorphism decreases endometrial cancer risk. Cancer Res 2004;64:1202-7.
19. Guillemette C, De Vivo I, Hankinson SE, et al. Association of genetic polymorphisms in UGT1A1 with breast cancer and plasma hormone levels. Cancer Epidemiol Biomarkers Prev 2001;10:711-4.
20. Hall D, Ybazeta G, Destro-Bisol G, Petzl-Erler ML, Di Rienzo A. Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates. Pharmacogenetics 1999;9:591-9.
21. Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A 1998;95:8170-4.
22. Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP- glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000;60:6921-6.
23. Sai K, Saeki M, Saito Y, et al. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther 2004;75:501-15.